Notably, different patterns of HNF4A usage were observed in precancer stages (e.g., AD v.s. SER, liver cirrhosis v.s. NAFLD, and SIM v.s. CAG). This evidence concerns the gene HNF4A and metabolic dysfunction-associated steatotic liver disease.